Biofrontera Inc. (BFRI)

NASDAQ: BFRI · IEX Real-Time Price · USD
1.540
+0.400 (35.09%)
Mar 28, 2024, 4:00 PM EDT - Market closed
35.09%
Market Cap 5.68M
Revenue (ttm) 34.07M
Net Income (ttm) -20.13M
Shares Out 5.09M
EPS (ttm) -13.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 248,040
Open 1.150
Previous Close 1.140
Day's Range 1.110 - 1.580
52-Week Range 0.610 - 13.480
Beta 0.54
Analysts Strong Buy
Price Target 18.00 (+1,068.83%)
Earnings Date Mar 15, 2024

About BFRI

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate seve... [Read more]

Sector Healthcare
IPO Date Oct 29, 2021
Employees 83
Stock Exchange NASDAQ
Ticker Symbol BFRI
Full Company Profile

Financial Performance

In 2023, Biofrontera's revenue was $34.07 million, an increase of 18.82% compared to the previous year's $28.67 million. Losses were -$20.13 million, 3045.5% more than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for BFRI stock is "Strong Buy" and the 12-month stock price forecast is $18.0.

Price Target
$18.0
(1,068.83% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announce...

1 day ago - Accesswire

CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

(This release corrects the release that was posted earlier on March 15, 2024 to update the Consolidated Balance Sheets) Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024 WOBU...

12 days ago - Accesswire

Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024 WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company spec...

12 days ago - Accesswire

Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024

WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will rep...

20 days ago - Accesswire

Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer

Provides Corporate Update on Financing and Investor Relations Toronto, Ontario--(Newsfile Corp. - March 5, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") is pleased t...

23 days ago - Newsfile Corp

Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules

Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Funding and rec...

4 weeks ago - Accesswire

Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG

Ameluz ® transfer price to Biofrontera AG reduced significantly Control of all US clinical trials of Ameluz transfers to Biofrontera Inc. on June 1 WOBURN, MA / ACCESSWIRE / February 20, 2024 / Biofro...

5 weeks ago - Accesswire

Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules

Company secures financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Funding and re...

5 weeks ago - Accesswire

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use

FDA has set a target action date of October 4, 2024 sNDA supported by two Phase 1 safety studies1 Aims at actinic keratosis (AK) field treatment with up to 3 tubes An estimated 13 million treatments g...

7 weeks ago - Accesswire

Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023

WOBURN, MA / ACCESSWIRE / January 11, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, ...

2 months ago - Accesswire

Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update

Conference call begins at 10:00 a.m. Eastern time on Friday, November 10, 2023 WOBURN, MA / ACCESSWIRE / November 9, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company ...

4 months ago - Accesswire

Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10

WOBURN, MA / ACCESSWIRE / November 3, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report fina...

5 months ago - Accesswire

Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules

WOBURN, MA / ACCESSWIRE / October 31, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products...

5 months ago - Accesswire

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

Patent Application Filed with Potential to Extend Ameluz® Protection to 2043 WOBURN, MA / ACCESSWIRE / October 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmace...

6 months ago - Accesswire

Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference

WOBURN, MA / ACCESSWIRE / October 5, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products,...

6 months ago - Accesswire

Biofrontera Inc. Announces Preliminary Third Quarter Revenues

Revenues Increased 101% to 108% Over the Prior-Year Quarter Affirms Guidance for Full-Year Revenue Growth of at Least 25% over 2022 WOBURN, MA / ACCESSWIRE / October 4, 2023 / Biofrontera Inc. (NASDAQ...

6 months ago - Accesswire

Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products,...

7 months ago - Accesswire

Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)

WOBURN, MA / ACCESSWIRE / August 28, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces posi...

7 months ago - Accesswire

Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update

Conference call begins at 8:30 a.m. Eastern time today WOBURN, MA / ACCESSWIRE / August 11, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the comme...

8 months ago - Accesswire

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma

Trial Results Expected in Mid-2024 WOBURN, MA / ACCESSWIRE / August 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of derm...

8 months ago - Accesswire

Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023

WOBURN, MA / ACCESSWIRE / August 4, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financ...

8 months ago - Accesswire

Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%

Management Reaffirms Full-Year 2023 Revenue Growth of at least 25% over Prior Year WOBURN, MA / ACCESSWIRE / July 13, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharm...

9 months ago - Accesswire

Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, a...

9 months ago - Accesswire

Biofrontera Inc. Announces 1-for-20 Reverse Stock Split

WOBURN, MA / ACCESSWIRE / July 3, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, an...

9 months ago - Accesswire

Biofrontera Inc. Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings Across the U.S.

WOBURN, MA / ACCESSWIRE / June 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, a...

10 months ago - Accesswire